Version Française
Logo retour accueil

Last news

  • IntegraGen's revenue increases 12% in 2014

    IntegraGen announced today the company's sales results for the year ending December 14, 2014 increased 12% in 2014 to € 6.04 million.

    Read more

  • Collaboration with PICCOLO study investigators

    IntegraGen has announced a collaboration with the team of investigators from the PICCOLO study to further validate the role of biomarker hsa-miR-31-3p in metastatic colorectal cancer (mCRC).

    Read more


IntegraGen's mission is to translate molecular research to clinical practice through the identification of novel genetic biomarkers and the subsequent commercialization of molecular diagnostic tests for autism and oncology based on these discoveries. The company also strives to be a leader in providing cutting edge genomic services to academic researchers and life sciences companies based on it's technological expertise and scientific know how.

Autism Oncology Services
Disclaimers - Mentions légales - Crédits